JOHNSON & JOHNSON
JNJNYSETrading Snapshot
- Day Range
- $269.47 β $272.48
- 52-Week Range
- $199.38 β $290.25
- Volume (shares)
- 11,918,787
- Avg Volume (shares)
- β
- Shares Outstanding
- 2.41B
- Next Earnings
- 2027-01-20
Fundamentals Snapshot
- Annual Revenue
- $94.19B
- Last Q Revenue
- $25.40B
- P/E Ratio
- 40.7
- P/S Ratio
- 6.6x
- EPS (TTM)
- $6.59
- Dividend Yield
- 1.94%
- Dilution (1yr)
- +0.5%
JOHNSON & JOHNSON
JNJAbout JOHNSON & JOHNSON
Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension. The MedTech segment includes a portfolio of products used in interventional solutions, orthopaedics, surgery, and vision categories. The company was founded by Robert Wood Johnson I, James Wood Johnson, and Edward Mead Johnson Sr. in 1887 and is headquartered in New Brunswick, NJ.
Otter Score Breakdown
How it's scoredFive components, each rated 1β5β and equally weighted (20%), averaged to a 0β100 score:π Quality β gross marginπ Growth β revenue YoYβοΈ Valuation β P/S ratioβ‘ Momentum β 30-day price changeπ§ Dilution β 1-yr share issuance (buybacks score higher)Latest News & Updates

The Dividend Investing Strategy That Made Geraldine Weiss a Wall Street Legend
Brokerage firms turned Weiss away when she tried to become an analyst. In 1966 she co-founded Investment Quality Trends and became the first woman to start an investment advisory service.

Johnson & Johnson Is on Track for $101 Billion in 2026 Sales. Is This Dividend King Still a Buy?
Johnson & Johnson is a leader in the pharmaceutical and medical device sectors. JNJ is a Dividend King with an above-market yield.

Johnson & Johnson vs. Pfizer: Which Healthcare Stock Is a Better Buy for 2027?
Johnson & Johnson maintains a diversified business model balancing pharmaceutical innovation with a massive medical technology segment. Pfizer is undergoing a significant transition by investing heavily in oncology and o

3 Reasons Dividend Aristocrats Belong in Your Roth IRA Before You Retire
At the 24% bracket, a $500,000 equal-weight position in three Dividend Aristocrats returns about $10,933 a year in dividends. In a taxable account, roughly $1,640 of that goes to the IRS every year at the 15% qualified r

Benzinga's 'Stock Whisper' Index: Five Stocks Investors Secretly Monitor But Don't Talk About Yet
Each week,Β Benzinga's Stock Whisper IndexΒ uses proprietary data and pattern recognition to highlight five stocks just under the surface that deserve attention.

5 Dividend Kings to Buy for Lifelong Income Before the End of November
Yield chasers keep learning the same lesson: A payout is only as durable as the cash flow behind it.